Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
Kristen N. Pallok and David A. Ansell’s “Should Clinicians Be Activists?” highlights how physician activists risk retaliation from “economically and socially” privileged physician leaders and organizational leadership who “have been trained to comply” with structural inequity.
AMA J Ethics. 2022;24(7):E694-696. doi:
10.1001/amajethics.2022.694.
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
The FDA's decision not to approve generic versions of original-formula OxyContin may keep drug costs high for patients with pain, but the benefits of the newer, abuse-resistant formulation outweigh this harm.
Transgender people planning a medical transition face decisions about family planning, fertility preservation, and how to access gender-affirming treatment.
AMA J Ethics. 2016;18(11):1119-1125. doi:
10.1001/journalofethics.2016.18.11.pfor2-1611.